|Product||Catalog No||Product Insert|
|gASCA IgG||S701100||click for pdf|
|ALCA IgG||L703011||click for pdf|
|ACCA IgA||C702100||click for pdf|
|AMCA IgG||M704100||click for pdf|
|Anti-C IgA||AC706100||click for pdf|
|Anti-L IgA||AL707100||click for pdf|
All kits have short incubation times and ready-to-use reagents.
Our IBDX® kits also have a break-a-well strips allowing high flexibility and economic use.
~ 80% sensitivity. More than any other IBD test on the market.
The IBDX® can identify between 35% to 56.4% of ASCA negative CD patients.
Employing gASCA, second generation of ASCA using advanced sugar technology, in combination with Anti-L, Anti-C, ALCA, ACCA and AMCA allows for 90-99% specificity for Chron's Disease
The IBDX® predict complications and need for abdominal surgery in Chron's disease patients as well as pouchitis in Ulcerative Colitis post-Op IPAA patients
IBDX® is fully validated for the pediatric population
The Management and staff of Glycominds are committed to meeting or exceeding our customer's expectations and all relevant regulatory requirements and to being a supplier known for the quality of every product and service we provide.
Our products and services shall be consistently safe for use, uniformly produced, and delivered on time.
This is a joint responsibility shared by each member of our organization. We are dedicated to continuous improvement of our overall quality performance in every facet of our operations and this dedication is manifested by the periodic establishment and achievement of quality goals and objectives at all levels of the organization.
We have established and implemented a system of quality in line with ISO 13485 international standards, and we regard this system as a means of continually improving our production and processes. >>
Phone: (+49)-511-6262 8630
FAX: (+49) -511-6262 8633